Yan Crystal Lihong, Grazette Luanda
Department of Medicine, Jackson Memorial Hospital, University of Miami, Miami, FL, United States.
Division of Cardiovascular Medicine, University of Miami Health System, Miami, FL, United States.
Front Cardiovasc Med. 2023 Apr 6;10:1150336. doi: 10.3389/fcvm.2023.1150336. eCollection 2023.
Heart failure is a clinical syndrome caused by structural cardiac abnormalities that lead to increased intracardiac pressures and decreased cardiac output. Following cardiovascular insult or direct myocardial injury, neurohormonal activation triggers hemodynamic changes and cardiac remodeling to preserve cardiac output. While initially adaptive, cardiac remodeling eventually causes pathologic changes in cardiac structure that often compromise cardiac function. Reverse remodeling is the regression of abnormal cardiac chamber geometry and function after myocardial injury. In recent years, several classes of therapeutics have been associated with greater likelihood of reverse remodeling. Heart failure recovery and heart failure remission, terms encompassing the clinical correlates of reverse remodeling, have been associated with improved survival in patients with heart failure with reduced ejection. As such, identifying predictors of heart failure recovery can have important implications for guiding clinical practice and therapeutic innovation. This review addresses the role of biomarkers and imaging monitoring in predicting structural, functional, and clinical recovery in patients with acute and chronic heart failure.
心力衰竭是一种由心脏结构异常引起的临床综合征,可导致心腔内压力升高和心输出量降低。在发生心血管损伤或直接心肌损伤后,神经激素激活会引发血流动力学变化和心脏重塑,以维持心输出量。虽然心脏重塑最初具有适应性,但最终会导致心脏结构发生病理变化,常常损害心脏功能。逆向重塑是心肌损伤后心脏腔室几何形状和功能异常的消退。近年来,几类治疗方法与更高的逆向重塑可能性相关。心力衰竭恢复和心力衰竭缓解这两个术语涵盖了逆向重塑的临床相关因素,与射血分数降低的心力衰竭患者生存率提高相关。因此,识别心力衰竭恢复的预测因素对于指导临床实践和治疗创新具有重要意义。本综述探讨了生物标志物和影像监测在预测急慢性心力衰竭患者结构、功能和临床恢复方面的作用。